Brain HealthBlood Pressure Drugs May Slow Parkinson's by Targeting Brain Renin-Angiotensin System
The renin-angiotensin system (RAS), long known for controlling blood pressure, also operates in the brain — and its malfunction may be a key driver of Parkinson's disease. When the angiotensin II pathway becomes overactive, it triggers oxidative stress, chronic brain inflammation, mitochondrial damage, and breakdown of the blood-brain barrier, all of which accelerate the death of dopamine-producing neurons. A counter-regulatory pathway involving ACE2 and angiotensin (1-7) appears to protect neurons, but is overwhelmed in Parkinson's. Crucially, common blood pressure medications — particularly ARBs and ACE inhibitors that can cross into the brain — show promise for slowing disease progression. This review synthesizes molecular, epidemiological, and early clinical evidence pointing to RAS modulation as a genuine disease-modifying strategy, not just symptom management.
